CAR T-Cell Therapy in Multiple Myeloma : Episode 7
Navigating Recovery: CAR-T Cell Therapy Experience
Panelists discuss how patients’ lives change after receiving chimeric antigen receptor (CAR) T-cell therapy, comparing the recovery process to previous lines of therapy, and how overall quality of life improves or changes following CAR T-cell treatment.
Video Player is loading.
EP: 1.Navigating the Myeloma Journey: Insights from Diagnosis to First-Line Treatment in Standard-Risk Patient
EP: 2.Exploring CAR-T Therapy: Discussing Its Introduction and Shared Decision-Making in Myeloma Treatment
EP: 3.CAR-T Therapy in Standard-Risk Multiple Myeloma: Rationale and Patient Preparation
EP: 4.CAR-T Therapy Journey: From Cell Collection to Managing Challenges
EP: 5.Preparing for CAR-T Therapy: Key Considerations and Timing in Multiple Myeloma Treatment
EP: 6.Managing CAR-T Therapy: Side Effect Monitoring and Collaborative Patient Care
Now Viewing
EP: 7.Navigating Recovery: CAR-T Cell Therapy Experience
EP: 8.Navigating the Long-Term Landscape: CAR-T Therapy Patient Monitoring and Care
EP: 9.Navigating My Myeloma Journey: Insights and Advice on CAR-T Therapy
EP: 10.The Future of CAR-T: Advancing Myeloma Treatment Strategies
Video content above is prompted by the following:
- How has your life changed since receiving chimeric antigen receptor (CAR) T-cell therapy?
- How would you compare the recovery process with your experience after your previous lines of therapy?
- How has your overall quality of life improved or changed compared with before CAR T-cell therapy?
Recent Videos
Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer
Second-Line Treatment for Gastric Adenocarcinoma
Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches
Gastric Adenocarcinoma: Current Treatment Landscape
Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW
Esophageal/Gastric Adenocarcinoma Standard of Care
BESPOKE: Study Design, Efficacy End Points and Methods
Related Content
